

Amneal & Impax Complete Combination

AMRX

LISTED

NYSE



A Strategic
Combination
for Long-Term
Growth

May 7, 2018

Safe Harbor Statement

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended). We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and include this statement for purposes of complying with the safe harbor provisions. Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future. The words such as "may," "will," "could," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "continue," and similar words are intended to identify estimates and forward-looking statements.

Such forward-looking statements are based on the expectations of Amneal Pharmaceuticals, Inc. ("our" or the "Company") and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements. Such risks and uncertainties include, but are not limited to (i) our ability to integrate the operations of Amneal Pharmaceuticals LLC ("Amneal") and Impax Laboratories, Inc. ("Impax") pursuant to the transactions (the "Combination") contemplated by that certain Business Combination Agreement dated as of October 17, 2017 by and among the Company, Amneal, Impax and K2 Merger Sub Corporation as amended by Amendment No. 1, dated November 21, 2017 and Amendment No. 2 dated December 16, 2017 and our ability to realize the anticipated synergies and other benefits of the Combination, (ii) the fact that certain of our stockholders holding over a majority of our shares (the "Amneal Group Members") may have interests different from those of our other stockholders, (iii) the transaction costs related to the Combination, (iv) results from the public unaudited financial information of Impax and Amneal may not be indicative of the Company's future operating performance, (v) business issues faced by either Amneal or Impax may be imputed to the operations of the Company, (vi) the impact of a separation of Impax or Amneal as a subsidiary of the Company, (vii) the change of control or early termination rights in certain of Impax's or Amneal's contracts that may be implicated by the Combination, (viii) payments required by the Company's Tax Receivables Agreement, (ix) the impact of global economic conditions, (x) our ability to successfully develop or commercialize new products, (xi) our ability to obtain exclusive marketing rights for our products or to introduce products on a timely basis, (xii) the competition we face in the pharmaceutical industry from brand and generic drug product companies, (xiii) our ability to manage our growth, (xiv) the impact of competition, (xv) the illegal distribution and sale by third parties of counterfeit versions of our products or of stolen products, (xvi) market perceptions of us and the safety and quality of our products, (xvii) the substantial portion of our total revenues derived from sales of a limited number of products, (xviii) our ability to develop, license or acquire and introduce new products on a timely basis, (xix) the ability of our approved products to achieve expected levels of market acceptance, (xx) the risk that we may discontinue the manufacture and distribution of certain existing products, (xxi) the impact of manufacturing or quality control problems, (xxii) product liability risks, (xxiii) risks related to changes in the regulatory environment, including United States federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws, (xxiv) changes to FDA product approval requirements, (xxv) risks related to federal regulation of arrangements between manufacturers of branded and generic products, (xxvi) the impact of healthcare reform, (xxvii) business interruptions at one of our few locations that produce the majority of our products, (xxviii) relationships with our major customers, (xxix) the continuing trend of consolidation of certain customer groups, (xxx) our reliance on certain licenses to proprietary technologies, (xxxi) our dependence on third party suppliers and distributors for raw materials for our products, (xxxii) the time necessary to develop generic and branded drug products, (xxxiii) our dependence on third parties for testing required for regulatory approval of our products, (xxxiv) our dependence on third party agreements for a portion of our product offerings, (xxxv) our ability to make acquisitions of or investments in complementary businesses and products, (xxxvi) regulatory oversight in international markets, (xxxvii) our increased exposure to tax liabilities and the impact of recent United State tax legislation, (xxxviii) third parties' infringement of our intellectual property rights, (xxxix) our involvement in various legal proceedings, (xl) increased government scrutiny related to our agreements to settle patent litigation, (xli) the impact of legal, regulatory and legislative strategies by our brand competitors, (xlii) the significant amount of resources we expend on research and development, (xliii) our substantial amount of indebtedness, (xliv) risks inherent in conducting clinical trials, (xlv) our reporting and payment obligations under the Medicaid and other government rebate programs, (xlvi) fluctuations in our operating results, (xlvii) adjustments to our reserves based on price adjustments and sales allowances, (xlviii) impact of impairment on our goodwill and other intangible assets, (xlix) investigations and litigation concerning the calculation of average wholesale prices, (l) cybersecurity and data leakage risks, (li) our ability to attract and retain talented employees and consultants, (lii) uncertainties involved in the preparation of our financial statements, (liii) impact of terrorist attacks and other acts of violence, (liv) expansion of social media platforms, (lv) our need to raise additional funds in the future, (lvi) the restrictions imposed by the terms of our credit agreement, (lvii) our ability to generate sufficient cash to service our indebtedness in the future and (lviii) such other factors as may be set forth in the Company's public filings with the Securities and Exchange Commission.

Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events or circumstances.

Trademarks referenced herein are the property of their respective owners.

©2018 Amneal Pharmaceuticals, Inc. All Rights Reserved.



Agenda

1 Strong Foundation for Growth • Paul Bisaro, Executive Chairman

2 The New Amneal • Rob Stewart, President & CEO

3 Financial Update & Capital Structure • Bryan Reasons, CFO

4 Closing Remarks • Rob Stewart

5 Questions & Answers




Strong Foundation for Growth

Paul Bisaro

Executive Chairman



A Strong Foundation to Deliver Long-Term Growth



Supported by Strong Cash Flow Targeted for Continued Investment in Growth Initiatives and Debt Reduction



Data as of April 1, 2018

The New Amneal


Robert Stewart

President and CEO



Well-Positioned Generic Pipeline to Drive Growth

With one of the largest U.S. generic products pipelines, we are positioned to be a leader in an evolving market and meet the ever-changing needs of tomorrow



Amneal data as of April 1, 2018. Includes products on file with the FDA and tentative approvals not yet launched.

¹Publicly disclosed data as of date listed: Teva – Dec. 31, 2017, Mylan – Apr. 11, 2018, Endo – Feb. 27, 2018, Akorn – Jan. 8, 2018, Lannett – Mar. 20, 2018. Excludes Indian Gx players.

Diversified Generic Products Commercial Portfolio

Our portfolio consists of more than 200 product families including difficult-to-manufacture and high barrier-to-entry products across multiple dosage forms




Yuvafem
(Estradiol Vaginal
Tablets)
~\$124mm+



Adrenaclick
(epinephrine
auto-injector)
~\$108mm+



Diclofenac
Sodium Topical
Gel 1%
~\$95mm+



Aspirin and
Extended-
Release
Dipyridamole
~\$90mm+



Oseltamivir
Capsules
~\$80mm+

Revenue Diversification - Top 5 Generic Product Revenue Contribution ~ 27%¹



For the Top 5 Generic products shown, net revenues reflect the last twelve months ended March 31, 2018.


¹ Top 5 generic product net revenue as a percent of total company net revenue for the last 12 months ended March 31, 2018.

Stable Cash Flow from Specialty Franchise

- Proprietary marketed products
 - Central nervous system disorders
 - Parasitic infections
 - Other therapeutic areas
- Established U.S. sales and marketing function
 - 130 sales reps
 - Primarily targeting neurologists, movement disorder specialists and other high-prescribing physicians in key markets

 **Zomig[®] Nasal Spray**
ZOLMITRIPTAN 2.5 mg / 5 mg

 **ALBENZA[®] 200MG**
(albendazole) chewable tablets

 **Rytary[®]**
(Carbidopa and Levodopa)
Extended-Release Capsules
23.75 mg / 95 mg • 36.25 mg / 145 mg
48.75 mg / 195 mg • 61.25 mg / 245 mg

 **Emverm[™]**
(mebendazole)
chewable tablet, USP
100 mg

Committed to Investing in Organic and External Opportunities to Create Long-Term Growth

Broad R&D Capabilities




ORAL SOLIDS & LIQUIDS

- IR/ER tablets
- Hard Gelatin Capsules
- Softgel Capsules
- Hormonals
- Controlled Substances
- Suspensions/Solutions



TOPICALS

- Gels
- Creams
- Ointments & Devices
- Hormonals



INJECTABLES & STERILE

- Peptides
- Microspheres
- Liposomes
- Hormonals
- General Injectables
- Oncology Injectables
- Ophthalmics
- Otics



TRANSDERMALS

- Matrix
- Hydrogel
- Form Fill Seal
- Hormonals





RESPIRATORY

- Metered Dose
- Dry Powder
- Nasal Spray Pumps
- BFS Inhalation

8 Global R&D Facilities Offering a Full Suite of In-House Capabilities

Diversified and High-Value Generic Pipeline

Approximately 284 total projects of which ~50% are high value opportunities¹



Filings 149 ANDAs²

U.S. Brand/Generic Sales ~\$75 Billion³

Development Pipeline: 135 projects²

U.S. Brand/Generic Sales ~\$45 Billion³



Note: % numbers in pie charts above represent percentage of products within each dosage form; \$ amounts represent respective sales data per IQVIA, as noted below.

¹ High value opportunities are eFTF, FTF, FTM and other high value opportunities with 0 to 3 competitors.

² Pipeline data as of April 1, 2018.

³ Sales data per IQVIA LTM February 2018

Pending ANDA Pipeline Offers Numerous Potential High-Value Opportunities to Drive Growth

A snapshot of only a few of the many high-value opportunities in our pipeline

Products	Brand	LTM IMS Sales
Dimethyl Fumarate DR Capsules	Tecfidera [®]	\$3,548
Glatiramer Injection 40mg	Copaxone HD [®]	\$3,457
Lisdexamfetamine Dimesylate Capsule	Vyvanse [®]	\$3,242
Lurasidone Tablets, 20mg, 40mg, 60mg, 80mg and 120mg	Latuda [®]	\$2,962
Emtricitabine + Tenofovir Disoproxil Fumarate	Truvada [®]	\$2,888
Cinacalcet HCl 30mg, 60mg and 90mg Tablets	Sensipar [®]	\$1,831
Teriflunomide Tablets	Aubagio [®]	\$1,487
Sildenafil Citrate Tablets	Viagra [®]	\$1,428
Abiraterone Acetate Tablets, 250mg	Zytiga [®]	\$1,393
Lacosamide Tablet	Vimpat [®]	\$1,191
Sodium Oxybate Oral Solution	Xyrem [®]	\$1,187
Imatinib Mesylate Tablets	Gleevec [®]	\$1,113
Mesalamine Delayed Release Tablet, 1.2gm	Lialda [®]	\$1,087
Testosterone Metered Gel 1.62% Pump	Androgel [®]	\$1,062
Biosimilar Opportunities		
Pegfilgrastim	Neulasta [®]	\$4,235
Bevacizumab	Avastin [®]	\$2,926
Filgrastim	Neupogen [®]	\$353



\$ millions.
Pending products as of April 1, 2018 with IQVIA sales greater than \$1 billion . IQVIA sales data as of February 2018.

Ongoing Commitment to Invest in Biosimilar Pipeline

New Partnership



- Amneal entered into a licensing and supply agreement for biosimilar candidate Avastin[®] (bevacizumab)
- Amneal will be the exclusive partner for the bevacizumab product in the US market
- Amneal will pay up-front, development and regulatory milestone payments to mAbxience as well as one-time commercial milestone payments on reaching pre-agreed sales targets in the market



Existing Partnership




Product Filed



Expected to be Filed 2H 2018


Diverse and Extensive Manufacturing Capabilities



Capacity to Support Growth for the Foreseeable Future; ~20 Billion Unit Capacity

Substantial Synergy Opportunity

Expected \$200+ million in annual incremental synergies within 3 years of close¹



¹ Estimated cash costs of \$65 to \$75 million to achieve expected synergies of approximately \$200 million.
² Run-rate cost synergies calculated using the estimated achieved net synergies within 24 months of the respective.

Amneal Acquires Gemini Laboratories LLC



- Gemini Laboratories is focused on marketing and sales of branded and specialty products
- Portfolio includes licensed and owned, niche and mature brands, and a pipeline of 505(b)(2)'s for niche therapeutic areas
- Operating synergy between Gemini and our Specialty Pharma division
- Lead product Unithroid® - detailed primarily to endocrinologists and high-prescribing primary care physicians
 - Unithroid® is a niche product in ~\$1 billion levothyroxine tabs market
 - Covered under a long-term license from Jerome Stevens Pharmaceuticals
 - Gemini holds distribution rights to the brand only, does not have generic distribution rights
 - Contract sales force through Syneos Health
- Gemini's 505(b)(2) development initiatives will fit strategically within the overall Amneal portfolio
 - Two products in active development

UNITHROID®
(Levothyroxine
Sodium Tablets, USP)

Financial Update & Capital Structure

Bryan Reasons

SVP, Chief Financial Officer



Combined Company 1Q18 Financial Results

\$ millions	1Q 2018	1Q 2017	Change 1Q/1Q
Total Revenues, net	\$417.5	\$410.1	2%
Generic revenues, net	\$358.3	\$359.8	0%
Specialty Pharma revenues, net	\$59.2	\$50.3	18%
GAAP Gross Margin	41.9%	34.4%	750bps
Adjusted Gross Margin	48.0%	50.3%	(230bps)
Net loss	(\$79.4)	(\$56.6)	(40%)
Adjusted EBITDA	\$95.9	\$96.0	0%

- Generic revenue drivers:
 - Product launches including oseltamivir, methylphenidate HCl ER and erythromycin
 - Reduced sales of budesonide, lidocaine, yuvafem-estradiol, mixed amphetamine salts and fenofibrate due to increased competition
 - Lower sales of epinephrine auto-injector due to recent supply shortage at third-party manufacturer
 - Lower than expected sales of aspirin dipyridamole ER due to raw material constraints
- Specialty revenue drivers:
 - Higher sales of Rytary[®], Zomig[®] and anthelmintic products
- GAAP Gross margin
 - Prior year included impact of impairment charge of ~\$39 million
- Adjusted gross margin:
 - Impacted by supply shortage and product sales mix
 - Certain pricing initiatives during 1Q18 that are expected to benefit future periods



The results presented represent the combination of the stand-alone results for each of Amneal Pharmaceuticals LLC and Impax Laboratories LLC (formerly Impax Laboratories, Inc.) for the periods ended March 31, 2018 and 2017. The results presented are not prepared on a pro forma basis and do not reflect the adjustments that would be necessary to present the financial results of the combined company as if the combination had been completed at the beginning of the periods presented.

Debt and Capital Structure

- Cash and cash equivalents of ~\$100 million¹
- \$2.7 billion term loan; LIBOR + 350 basis points
- \$500 million revolver available
- Estimated share count:
 - Legacy Impax: ~75 million
 - New shares: ~225 million
 - Total shares: ~300 million²

Cash Flow Targeted for Debt Reduction and Investment in Growth Initiatives



¹ Data as of May 4, 2018.

² Total shares consist of (i) approximately 75 million Class A shares (including shares underlying options) issued to former Impax stockholders, (ii) approximately 47 million Class A and Class B-1 shares sold to PIPE investors and (iii) approximately 179 million Class A shares issuable on exchange of LLC units held by the Amneal Group (subject to a 180 day lock-up and with a corresponding number of Class B shares issued to provide for voting rights). Approximately 110 million Class A shares are currently listed and publicly traded on the NYSE.

Closing Remarks

Robert Stewart

President and CEO



2018 Key Guidance Assumptions

- Growth in adjusted EBITDA weighted towards second half of 2018 due to estimated timing of new approvals and launches
- Generic division growth driven by new product launches which are expected to more than offset additional competition on existing portfolio
 - Potential opportunity to launch approximately 60 generic products
 - Year-to-date; 11 ANDAs approved and 11 products launched
- Specialty Pharma growth driven by Rytary[®], Zomig[®] nasal spray and Emverm[®]
- Delivering on investments in R&D
 - Currently targeting to file more than 30 ANDAs
 - Initiating phase 3 study for IPX203
- Targeting synergies of \$30 to \$35 million
 - 50% R&D, 30% SG&A, 20% Manufacturing

Full Year 2018 Financial Guidance


	Guidance Range Full Year 2018
Adjusted Gross Margins	50% - 55%
Adjusted R&D Expense as a % of Total Revenues ¹	10% - 15%
Adjusted SG&A Expense as a % of Total Revenues	13% - 16%
Adjusted EBITDA ²	\$600 to \$650 million
Adjusted EPS	\$0.95 - \$1.10
Adjusted Effective Tax Rate	20% to 22%
Capital Expenditures	\$80 to \$100 million
Diluted Shares Outstanding	Approximately 300 million

¹ Targeted annualized R&D spend is approximately 10% of total revenues. Delayed closing of business combination resulting in higher R&D spend in 2018.

² Includes cost synergies of ~ \$30 - \$35 million currently expected to be realized in 2018.

Amneal's full year 2018 estimates are based on management's current expectations, including with respect to prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The Company does not provide forward-looking guidance metrics as outlined below on a GAAP basis. Consequently, the Company cannot provide a reconciliation between non-GAAP expectations and corresponding GAAP measures without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses, asset impairments and certain and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. The following statements are forward looking and actual results could differ materially depending on market conditions and the factors set forth under "Safe Harbor" below.

Adjusted EBITDA Bridge to Full Year 2018 Guidance



\$ millions

Focused on Operational Execution...

- Rapidly and seamlessly combine Amneal and Impax
- Focus on synergy capture and cost control
- Maintain high level of quality and compliance
- Continue to provide superior service to our customers
- Maximize value of enhanced commercial portfolio to grow revenue and profits



...And Continued Investment in Growth Initiatives


OUR PORTFOLIO FOCUS

Generics | Specialty Products | Biosimilars

- Invest in organic growth through focused R&D
- Pursue creative business development to strengthen our franchises and other adjacencies



Questions & Answers



Appendix & Non-GAAP Reconciliations



Disclosed ANDA Pending Pipeline

Product	Brand	LTM IMS Sales	Product	Brand	LTM IMS Sales
Pemetrexed injection	Alimta®	\$1,053	Pitavastatin Calcium Tablet	Livalo®	\$292
Lubiprostone Capsule	Amitiza®	\$489	Guaifenesin Tablet	Mucinex®	\$75
Testosterone Gel 1.62%	AndroGel®	\$1,062	Guaifenesin + Dextromethorphan HBr	Mucinex® DM	\$61
Teriflunomide Tablet	Aubagio®	\$1,487	Dronaderone Tablet	Multaq®	\$450
Testosterone Topical Solution	Axiron®	\$158	Ritonavir Tablet	Norvir®	\$200
Risedronate Sodium DR tablet	Atelvia®	\$18	Saxagliptin HCl Tablet	Onglyza®	\$404
Ticagrelor Tablet	Brilinta®	\$749	Doxycycline ER Capsule 40mg	Oracea®	\$300
Exenatide Injection	Byetta®	\$237	Oxycodone ER Tablet	OxyContin®	\$1,875
Mesalamine Rectal Suppository	Canasa®	\$245	Diclofenac Na Topical Solution 2%	Pennsaid® 2%	\$953
Colchicine Tablet	Colcrys®	\$574	Dexmedetomidine HCl Injection	Precedex®	\$119
Glatiramer Injection	Copaxone®HD	\$3,457	Asenapine Maleate Sublingual Tablet	Saphris®	\$292
Carvedilol ER capsule	Coreg CR®	\$192	Cinacalcet HCl Tablet	Sensipar®	\$1,739
Prasugrel HCl Tablet	Effient®	\$516	Quetiapine Fumarate ER Tablet	Seroquel® XR	\$629
Apixaban IR tablet	Eliquis®	\$4,956	Dimethyl Fumarate DR Capsule	Tecfidera®	\$3,548
Darifenacin HBr ER Tablet	Enablex®	\$35	Fesoterodine Fumarate Tablet	Toviaz®	\$200
Rivastigmine TDS Patch	Exelon®	\$262	Emtricitabine + Tenofovir DF Tablet	Truvada®	\$2,888
Fulvestrant Injection	Faslodex®	\$503	Bortezomib Injection	Velcade®	\$637
Fentanyl Buccal IR tablet	Fentora®	\$103	Sildenafil Citrate Tablet	Viagra®	\$1,428
Levomilnacipran HCl ER Capsule	Fetzima®	\$118	Lacosamide Tablet	Vimpat®	\$1,191
Imatinib Mesylate Tablet	Gleevec®	\$1,113	Lisdexamfetamine Dimesylate Capsule	Vyvanse®	\$3,242
Saxagliptin HCl + Metformin ER Tablet	Kombiglyze® XR	\$194	Colesevelam IR tablet	Welchol®	\$526
Lamotrigine ER Tablet	Lamictal® XR	\$323	Sodium Oxybate Solution	Xyrem®	\$1,187
Lurasidone HCl Tablet	Latuda®	\$2,962	Azithromycin Powder for Suspension	Zithromax®	\$74
Mesalamine DR Tablet	Lialda®	\$1,087	Abiraterone Acetate Tablet	Zytiga®	\$1,393



\$ millions.

Source of sales data: IMS NPS February 2018; Pipeline data as of April 1, 2018.

GAAP to Non-GAAP Reconciliation

The following table reconciles combined Amneal Pharmaceuticals LLC and Impax Laboratories LLC reported cost of revenues to adjusted cost of revenues for purposes of determining adjusted gross margin (unaudited, in thousands).

	Three months ended	
	March 31, 2018	March 31, 2017
Total revenues	\$ 417,544	\$ 410,084
Cost of revenues	242,669	\$ 229,897
Cost of revenues impairment charges	-	39,280
Adjusted to deduct:		
Amortization	16,233	18,118
Intangible asset impairment charges	-	39,280
Restructuring and severance charges	2,555	7,775
Inventory related charges	6,889	-
Adjusted cost of revenues	\$ 216,992	\$ 204,004
Adjusted gross profit ^(a)	\$ 200,552	\$ 206,080
Adjusted gross margin ^(a)	48.0%	50.3%

^(a) Adjusted gross profit is calculated as total revenues less adjusted cost of revenues. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.

GAAP to Non-GAAP Reconciliation

The following table reconciles the combined Amneal Pharmaceuticals LLC and Impax Laboratories LLC reported net loss to adjusted EBITDA: (unaudited, in thousands).

	Three months ended	
	March 31, 2018	March 31, 2017
Net loss	\$ (79,397)	\$ (56,578)
Adjusted to add (deduct):		
Interest expense, net	34,743	27,387
Income taxes	(6,926)	31,904
Depreciation and amortization	32,727	34,698
EBITDA	(18,853)	37,411
Adjusted to add (deduct):		
Gemini Laboratories, LLC EBITDA ^(a)	4,100	4,150
Share-based compensation expense	4,816	6,957
Business development expenses ^(b)	13,679	50
Restructuring and severance charges	4,900	9,455
Loss on extinguishment of debt	-	1,215
Inventory related charges	6,889	-
Litigation, settlements and related charges ^(c)	90,099	(495)
Asset impairment charges	53	45,359
Royalty expense	-	3,763
Exchange gain	(9,486)	(14,596)
Other	(293)	2,709
Adjusted EBITDA	\$ 95,904	\$ 95,978

(a) Represents the EBITDA generated by Gemini Laboratories, LLC, which Amneal acquired on May 7, 2018.

(b) Primarily represents professional fees incurred in connection with the combination of Amneal and Impax.

(c) During March 2018, Impax separately settled claims associated with its Solodyn® Antitrust Class Actions for a total settlement of \$84.5 million.

